Iambic Therapeutics prices IPO at $16 per share, lists on Nasdaq as IAM

Iambic Therapeutics, Inc. priced its initial public offering at $16.00 per share, offering 9,375,000 shares of common stock, according to a prospectus filed October 14, 2026. The underwriters expect to deliver the shares to purchasers on or about October 16, 2026.¹ The stock has been approved for listing on The Nasdaq Global Select Market under the symbol "IAM."¹

Two existing investors signaled interest in the deal. ARK Investment Management LLC, already a company investor, along with Duquesne Family Office LLC, indicated interest in buying up to a combined $60.0 million worth of shares at the IPO price, on the same terms as other purchasers.¹ The company noted such indications are non-binding.

Iambic describes itself as a technology and clinical-stage life sciences company that integrates proprietary, large-scale artificial intelligence with automated, scalable chemistry and biology experimentation.¹ Its lead program, IAM1363, is an oral, highly selective, pan-mutant, and brain-penetrant small molecule inhibitor of HER2¹, which is in an ongoing Phase 1/1b basket trial across multiple centers in patients with advanced HER2-altered solid tumors, with the company anticipating a registrational trial as early as 2027, subject to regulatory feedback.¹

The company also disclosed it submitted an IND application to the FDA for IAM217 on September 30, 2026, and plans to begin a Phase 1/2 trial pending regulatory clearance.¹

Financially, net losses totaled $77.3 million in 2025 and $47.9 million in 2024, with a $50.1 million loss for the six months ended June 30, 2026.¹ As of June 30, 2026, the accumulated deficit stood at $245.3 million.¹ Net proceeds from the offering are expected to be approximately $135.0 million, or about $155.9 million if underwriters fully exercise their option.¹